Cannabis Policy
Multiple Case Studies Show Potential Danger of Cannabis Contaminants
Preventive steps and remediative action are required to reduce the prevalence of contamination from microbes, heavy metals and, pesticides.
CBD Market Set to Grow as Regulatory Change Looms in U.S.
The market for cannabis and hemp products has seen a low-key but potentially huge step forward in recent weeks.
A Big Step Forward for Medical Marijuana
Medical marijuana has picked up considerable momentum after a U.S. FDA advisory panel unanimously recommended approval of GW Pharmaceuticals' epilepsy medication, Epidolex.
Medical Cannabis and the Challenge for Regulation of Medicines
Reviews of scientific evidence show promising findings for some, but not all, conditions for which cannabis is considered a treatment – and this evidence is difficult to untangle.
Advancing Cannabinoid Research in Australia
Pioneering researchers are developing cannabinoid formulations to help doctors and patients control their dosing, as well as help researchers better study the drug in clinical trials.
Monopoly on FDA-approved Cannabis May Hold Back Parkinson's Drug Development
GB Sciences are looking for international suppliers that produce minor cannabinoids and terpenes to ensure that it can expand testing beyond their planned, initial Phase 0 Trial.
Texas Moving to Ban the Sale of All CBD Products
The Medical Cannabis Association of Texas is urging the Texas Department of State Health Services not to take action on their proposal to ban the sales of all CBD oil products sold in the state.
Legalized Medical Cannabis Lowers Opioid Use
States that have approved medical cannabis laws saw a dramatic reduction in prescription opioid use.
Industry Leader Says Sessions Has Given Cannabis Industry the Green Light
Sessions told students in a speech that Federal law enforcement lacks the resources to take on “routine cases” and will continue to only focus on gangs and larger conspiracies.
